Royal Bank of Canadahttps://www.rbcroyalbank.com/personal.htmlhttps://www.rbcroyalbank.com/personal.htmlInsights1200630enCA
Datum[@Name='Source DCR']
2020-05-26New business models emergeWill genetics usher in a new era of healthcare? Is the entire health ecosystem ready for reinvention? Can digital healthcare in life sciences exceed patient expectations?Expanding Ecosystems3/assets/rbccm/images/gib/healthcare/article_3_thumbnail_sm.jpg/assets/rbccm/images/gib/healthcare/article_3_thumbnail.jpg<h3>Shifting Paradigms</h3>
<p>As the convergence of healthcare and technology has accelerated, new business models are rapidly emerging. </p>
<p>In the traditional biopharma model, the customer would be a physician, R&D tools would be chemical or biological, the end product a pill or vial, and the competitors pharma and biotech players.</p>
<p>The digital revolution in healthcare is shifting this long-established paradigm. Today, biopharma companies’ customer groups have grown to include patients of all ages, providers and payers—all equipped with smartphones and apps that generate a vast amount of digital information to empower their decision-making. R&D has added genetic information and digital capability to its toolset. The end product has broadened beyond the pill to include health outcomes enabled by digital devices and therapeutics. And the competitive set has seen the addition of technology players, including consumer-focused apps and online services, as well as digital health and digital therapeutics firms.</p>
<p class="photo-frame text-center"><img style="width: 100%;" src="/assets/rbccm/images/gib/healthcare/Healthcare-Article-3-Graph-1.png" alt="" /></p>
<h3>A Changing Ecosystem</h3>
<p>Indeed, digital and AI applications are radically changing key areas of the biopharma ecosystem and how patients manage their healthcare.</p>
<p>In pre-clinical research, technology is enabling everything from a deeper mining of literature, to predictive modeling and gene-function annotation. Digital apps are simulating molecular dynamics and pushing the limits of cellular imaging.</p>
<p>In clinical trials, digital transformation is helping to automate testing procedures, build global patient databases and collect real-world data.</p>
<p>In diagnostics, tech powers digital pathology, home-based body diagnosis, and computational analysis of tissue arrays. Just like your car leaves the factory with hundreds of sensors that can trigger the check engine light, humans will have wearable and/or implantable sensors to alert them when something is not functioning properly. Another burgeoning area is immune cell monitoring and digital analysis through just a finger prick.</p>
<p>At the point of patient care, digital applications are already delivering virtual consultations, remote monitoring, VR-based cognitive therapy and digital Rx. Demand for telehealth services and health-based social platforms is also increasing and especially vital in a world facing new challenges such as the COVID-19 pandemic.</p>
<p><img src="/assets/rbccm/images/gib/healthcare/healthcare-article-3-graph-2.png" alt="AI and Digital applications are changing key areas of the Healthcare Ecosystem" /></p>
<div id="similar-to-this" style="border-top: 2px #E6E6E7 dotted; border-bottom: 2px #E6E6E7 dotted; margin: 35px 0; padding: 25px;">
<h4 style="font-size: 18px; letter-spacing: 0.5px; border-bottom: 3px #FEDF01 solid; padding: 0 0 8px 0; margin-bottom: 15px;">Similar to this</h4>
</div>
<h3>Digital Transformation</h3>
<p>The digital revolution presents both threats and opportunities to incumbent biopharma companies. Tech is powering efficiencies in all stages of the current ecosystem and is also enabling healthcare providers to expand their capabilities from treatment to prevention.</p>
<div class="quotebox">
<p>“Tech is powering efficiencies in all stages of the current ecosystem and is also enabling healthcare providers to expand their capabilities.”</p>
<p class="attribution" style="color: #0070a3;">– Greg Wiederrecht, Ph.D.</p>
<div class="quote-share">
<p style="display: inline-block;"><span style="margin-right: 15px;">Share </span><a class="blue-circle-outline-sm" href="https://www.linkedin.com/shareArticle?mini=true&url=https%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge&title=New%20healthcare%20business%20models%20emerge&source=www.rbccm.com" target="_blank" rel="noopener" aria-label="Connect by LinkedIn"><em class="fa fa-linkedin" style="color: #0051a5; margin-left: 3px;"> </em></a> <a class="blue-circle-outline-sm" href="https://twitter.com/home?status=New%20business%20models%20emerge%20https%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge" target="_blank" rel="noopener" aria-label="Connect by X"><em class="fa fa-twitter" style="color: #0051a5; margin-left: 3px;"> </em></a> <a class="blue-circle-outline-sm" href="mailto:?subject=New%20business%20models%20emerge&body=I%20found%20this%20insights%20piece%20from%20RBC%20Capital%20Markets%20informative%20and%20thought%20it%20might%20be%20of%20interest%20to%20you%3A%0D%0Dhttps%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge&title=New business models emerge" aria-label="Connect by Email"><em class="fa fa-envelope" style="color: #0051a5; margin-left: 3px;"> </em></a></p>
</div>
</div>
<p> </p>
<p>The increased digitization of human experiences gives access to a wealth of information and knowledge that could help intervene before disease has a chance to strike. A prime example of this is collating data from an Apple Watch to screen for irregular heart rhythms and detect undiagnosed atrial fibrillation. At the other end of the spectrum, digital transformation allows a completely new class of therapies such as digital therapeutics to support specific disorders.</p>
<p>McKinsey and Company’s international survey shows that more than 75% of patients expect to use digital healthcare services in the future.<sup>1</sup> Patients are seeking technology that delivers a level of care they can rely on and trust. Ultimately, the aim of the digital revolution is to develop healthier societies and lower the cost of care.</p>
<p style="word-wrap: break-word;"><sup>1 Source: McKinsey and Company, Healthcare’s Digital Future, July 2014. https://www.mckinsey.com/~/media/McKinsey/Industries/Healthcare%20Systems%20and%20Services/Our%20Insights/Healthcares%20digital%20future/Healthcares%20digital%20future.ashx</sup></p><ul>
<li>Customer groups, R&D and competitors are all rapidly expanding</li>
<li>Tech is reinventing every facet of the biopharma ecosystem</li>
<li>Innovations in patient care is driving adoption of digital services</li>
</ul>text2 min1 minHealthcare Models, Digital Healthcare, Digital Healthcare Apps, Digital Health Diagnostics, Expanding R&D, Healthcare & Tech Convergence, Healthcare Services, Clinical Trials, Remote Patient Monitoring, Digital Therapeutics, Biopharma ecosystem, Cost of CareN/templatedata/rbccm/episode/data/healthcare/amazon_cvs_and_google_healthcare_reimagined/templatedata/rbccm/episode/data/healthcare/big_tech_vs_big_pharma/templatedata/rbccm/episode/data/healthcare/the_healthcare_data_explosionGreg Wiederrecht, Ph.D./assets/rbccm/images/gib/healthcare/greg-wiederrecht.jpgManaging Director, Healthcare Investment Bankinggreg.wiederrecht@rbccm.comhttps://www.linkedin.com/in/gregwiederrecht/Sasson Darwish/assets/rbccm/images/gib/healthcare/sasson-darwish.jpgManaging Director, AI, Analytics and IoT & Israel Country Coverage, Global Technology Investment Bankingsasson.darwish@rbccm.com https://www.linkedin.com/in/sassdarwish/Andrew Callaway/assets/rbccm/images/gib/healthcare/andrew-callaway.jpgManaging Director, Global Head of Healthcare Investment Bankingandrew.callaway@rbccm.comhttps://www.linkedin.com/in/andrew-cal-callaway
DEBUG: DCR
DCR
Royal Bank of Canadahttps://www.rbcroyalbank.com/personal.htmlhttps://www.rbcroyalbank.com/personal.htmlInsights1200630enCA
DCR
2020-05-26New business models emergeWill genetics usher in a new era of healthcare? Is the entire health ecosystem ready for reinvention? Can digital healthcare in life sciences exceed patient expectations?Expanding Ecosystems3/assets/rbccm/images/gib/healthcare/article_3_thumbnail_sm.jpg/assets/rbccm/images/gib/healthcare/article_3_thumbnail.jpg<h3>Shifting Paradigms</h3>
<p>As the convergence of healthcare and technology has accelerated, new business models are rapidly emerging. </p>
<p>In the traditional biopharma model, the customer would be a physician, R&D tools would be chemical or biological, the end product a pill or vial, and the competitors pharma and biotech players.</p>
<p>The digital revolution in healthcare is shifting this long-established paradigm. Today, biopharma companies’ customer groups have grown to include patients of all ages, providers and payers—all equipped with smartphones and apps that generate a vast amount of digital information to empower their decision-making. R&D has added genetic information and digital capability to its toolset. The end product has broadened beyond the pill to include health outcomes enabled by digital devices and therapeutics. And the competitive set has seen the addition of technology players, including consumer-focused apps and online services, as well as digital health and digital therapeutics firms.</p>
<p class="photo-frame text-center"><img style="width: 100%;" src="/assets/rbccm/images/gib/healthcare/Healthcare-Article-3-Graph-1.png" alt="" /></p>
<h3>A Changing Ecosystem</h3>
<p>Indeed, digital and AI applications are radically changing key areas of the biopharma ecosystem and how patients manage their healthcare.</p>
<p>In pre-clinical research, technology is enabling everything from a deeper mining of literature, to predictive modeling and gene-function annotation. Digital apps are simulating molecular dynamics and pushing the limits of cellular imaging.</p>
<p>In clinical trials, digital transformation is helping to automate testing procedures, build global patient databases and collect real-world data.</p>
<p>In diagnostics, tech powers digital pathology, home-based body diagnosis, and computational analysis of tissue arrays. Just like your car leaves the factory with hundreds of sensors that can trigger the check engine light, humans will have wearable and/or implantable sensors to alert them when something is not functioning properly. Another burgeoning area is immune cell monitoring and digital analysis through just a finger prick.</p>
<p>At the point of patient care, digital applications are already delivering virtual consultations, remote monitoring, VR-based cognitive therapy and digital Rx. Demand for telehealth services and health-based social platforms is also increasing and especially vital in a world facing new challenges such as the COVID-19 pandemic.</p>
<p><img src="/assets/rbccm/images/gib/healthcare/healthcare-article-3-graph-2.png" alt="AI and Digital applications are changing key areas of the Healthcare Ecosystem" /></p>
<div id="similar-to-this" style="border-top: 2px #E6E6E7 dotted; border-bottom: 2px #E6E6E7 dotted; margin: 35px 0; padding: 25px;">
<h4 style="font-size: 18px; letter-spacing: 0.5px; border-bottom: 3px #FEDF01 solid; padding: 0 0 8px 0; margin-bottom: 15px;">Similar to this</h4>
</div>
<h3>Digital Transformation</h3>
<p>The digital revolution presents both threats and opportunities to incumbent biopharma companies. Tech is powering efficiencies in all stages of the current ecosystem and is also enabling healthcare providers to expand their capabilities from treatment to prevention.</p>
<div class="quotebox">
<p>“Tech is powering efficiencies in all stages of the current ecosystem and is also enabling healthcare providers to expand their capabilities.”</p>
<p class="attribution" style="color: #0070a3;">– Greg Wiederrecht, Ph.D.</p>
<div class="quote-share">
<p style="display: inline-block;"><span style="margin-right: 15px;">Share </span><a class="blue-circle-outline-sm" href="https://www.linkedin.com/shareArticle?mini=true&url=https%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge&title=New%20healthcare%20business%20models%20emerge&source=www.rbccm.com" target="_blank" rel="noopener" aria-label="Connect by LinkedIn"><em class="fa fa-linkedin" style="color: #0051a5; margin-left: 3px;"> </em></a> <a class="blue-circle-outline-sm" href="https://twitter.com/home?status=New%20business%20models%20emerge%20https%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge" target="_blank" rel="noopener" aria-label="Connect by X"><em class="fa fa-twitter" style="color: #0051a5; margin-left: 3px;"> </em></a> <a class="blue-circle-outline-sm" href="mailto:?subject=New%20business%20models%20emerge&body=I%20found%20this%20insights%20piece%20from%20RBC%20Capital%20Markets%20informative%20and%20thought%20it%20might%20be%20of%20interest%20to%20you%3A%0D%0Dhttps%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge&title=New business models emerge" aria-label="Connect by Email"><em class="fa fa-envelope" style="color: #0051a5; margin-left: 3px;"> </em></a></p>
</div>
</div>
<p> </p>
<p>The increased digitization of human experiences gives access to a wealth of information and knowledge that could help intervene before disease has a chance to strike. A prime example of this is collating data from an Apple Watch to screen for irregular heart rhythms and detect undiagnosed atrial fibrillation. At the other end of the spectrum, digital transformation allows a completely new class of therapies such as digital therapeutics to support specific disorders.</p>
<p>McKinsey and Company’s international survey shows that more than 75% of patients expect to use digital healthcare services in the future.<sup>1</sup> Patients are seeking technology that delivers a level of care they can rely on and trust. Ultimately, the aim of the digital revolution is to develop healthier societies and lower the cost of care.</p>
<p style="word-wrap: break-word;"><sup>1 Source: McKinsey and Company, Healthcare’s Digital Future, July 2014. https://www.mckinsey.com/~/media/McKinsey/Industries/Healthcare%20Systems%20and%20Services/Our%20Insights/Healthcares%20digital%20future/Healthcares%20digital%20future.ashx</sup></p><ul>
<li>Customer groups, R&D and competitors are all rapidly expanding</li>
<li>Tech is reinventing every facet of the biopharma ecosystem</li>
<li>Innovations in patient care is driving adoption of digital services</li>
</ul>text2 min1 minHealthcare Models, Digital Healthcare, Digital Healthcare Apps, Digital Health Diagnostics, Expanding R&D, Healthcare & Tech Convergence, Healthcare Services, Clinical Trials, Remote Patient Monitoring, Digital Therapeutics, Biopharma ecosystem, Cost of CareN/templatedata/rbccm/episode/data/healthcare/amazon_cvs_and_google_healthcare_reimagined/templatedata/rbccm/episode/data/healthcare/big_tech_vs_big_pharma/templatedata/rbccm/episode/data/healthcare/the_healthcare_data_explosionGreg Wiederrecht, Ph.D./assets/rbccm/images/gib/healthcare/greg-wiederrecht.jpgManaging Director, Healthcare Investment Bankinggreg.wiederrecht@rbccm.comhttps://www.linkedin.com/in/gregwiederrecht/Sasson Darwish/assets/rbccm/images/gib/healthcare/sasson-darwish.jpgManaging Director, AI, Analytics and IoT & Israel Country Coverage, Global Technology Investment Bankingsasson.darwish@rbccm.com https://www.linkedin.com/in/sassdarwish/Andrew Callaway/assets/rbccm/images/gib/healthcare/andrew-callaway.jpgManaging Director, Global Head of Healthcare Investment Bankingandrew.callaway@rbccm.comhttps://www.linkedin.com/in/andrew-cal-callaway
12025-01-24Why invest in the U.K.? Five takeaways from the 2025 U.K. Focus ConferenceLast month, we held the inaugural U.K. Focus Conference, hosted by Adam Miller, Head of U.K. Corporate Broking at RBC Capital Markets, where we invited investors to hear from Charlie Walker, Deputy Chief Executive Officer at the London Stock Exchange Plc; Adam McConkey, Head of Team & Co-Lead Portfolio Manager at Lombard Odier; and Anne Christine Farstad, Equity Portfolio Manager at MFS Investment Management, sharing their insights in a session on the key drivers and opportunities in the U.K. noneInsights<li><a href="/en/">Home</a></li><li><a href="/en/insights.page">Insights </a></li><li><a href="/en/insights/european-insights.page">European Insights</a></li>Home | Insights | European Insights/assets/rbccm/images/insights/2025/20250115-why-invest-uk-th.jpg/assets/rbccm/images/insights/2025/20250115-why-invest-uk-banner.jpghttps://www.rbccm.com/en/story/story.page?dcr=templatedata/article/story/data/2025/01/why-invest-in-the-uk-six-takeaways-from-the-2025-uk-focus-conferencenone<p> </p>
<p>The U.K. equity market took center stage in a recent discussion featuring industry leaders exploring key developments from 2024 and trends shaping 2025. Charlie Walker, Deputy Chief Executive Officer at the London Stock Exchange Plc; Adam McConkey, Head of Team & Co-Lead Portfolio Manager at Lombard Odier; and Anne Christine Farstad, Equity Portfolio Manager at MFS Investment Management, shared their insights in a session moderated by Adam Miller, Head of U.K. Corporate Broking at RBC Capital Markets.</p>
<p>With questions around the U.K.’s positioning in global markets, the conversation delved into a critical theme: the gap between perception and reality in U.K. equities.</p>
<h2>1. The US Outperformed the European Markets Again in 2024</h2>
<ul>
<li>The S&P 500 had an impressive year, rising by 23% though heavily influenced by gains by the 'Mag 7' tech giants. Excluding these seven companies, the S&P 500 gained a more modest 7%</li>
<li>In contrast, the UK market has lagged behind, partly due to underlying skepticism and a lack of investor confidence which does not reflect the actual market fundamentals</li>
<li>The discussion highlighted a critical underlying issue where UK equities have been overshadowed by their US counterparts, exacerbating the performance gap</li>
</ul>
<h2>2. Understanding the UK-US Valuation Gap</h2>
<ul>
<li>The valuation disparity between UK and US markets is significant, with an 8x PE valuation gap, and when including the 'Mag 7', this gap widens to 12x</li>
<li>Global momentum investing, where investment decisions are driven by recent performance rather than fundamental value, has favored US markets</li>
<li>This approach is tied to US exceptionalism and a higher RoE of around 20% compared to the UK's 15% and Japan's 10%</li>
<li>UK markets need to promote their value proposition strategically to bridge this gap and attract global investment</li>
</ul>
<h2>3. Reviving the UK Market Through Listing and Pension Reforms</h2>
<ul>
<li>Recent years in the UK have been dominated by major events such as Brexit and the COVID-19 pandemic</li>
<li>It's only in the last 18 months that policy changes and regulatory reforms, like new listing rules, have become the focus for the UK</li>
<li>Notably, the discussion about the pensions industry is pivotal, given that UK pension allocations to UK assets have plummeted from 48% in 2000 to between 5-10% now</li>
<li>The UK has the second-largest pool of long-term capital globally, and the country needs to harness this capital better to support its domestic market and attract new listings</li>
</ul>
<h2>4. US Listings: Not Always Greener for UK Companies</h2>
<ul>
<li>There's a prevalent perception that the US market is far superior, leading many UK companies to list in the US</li>
<li>However, the data shows a mixed results: 20 of the UK companies that listed in the US in the past 10 years have had varied success with eight trading down by 79% on average, four doing well (like ARM), and eight delisted for diverse reasons, suggesting that the grass is not always greener on the other side</li>
<li>The challenge for the UK is to support its companies better through the various growth stages domestically, preventing capital and talent from migrating to the US</li>
</ul>
<h2>5. Outlook for 2025 and Key Desires</h2>
<ul>
<li>Corporate confidence in the UK is relatively high, especially with current valuations</li>
<li>A key point of discussion was the prevalent public M&A activity in the UK, with companies being acquired at premiums of 75%-100%. This seems to contradict the negative sentiment around UK stocks, suggesting that despite low perceived growth and mature stories, there is significant value there</li>
<li>The panel speakers agreed on the need for ongoing pension reforms to foster a more robust equity culture, akin to the 401k system in the US, which could stabilize and grow the market</li>
<li>Additionally, the speakers expressed hope for a relative underperformance of momentum strategies, signaling a shift away from the current trend-centric investing towards more fundamentally driven decisions</li>
</ul>
<p>Overall, the panelists agreed that the UK continues to be a compelling investment across a number of asset classes. If policy reforms through 2025 can continue to reinvigorate interest in the market and bring new companies to investors’ attention, the outlook will continue to be positive.</p><ul>
<li>The US Outperformed the European Markets Again in 2024.</li>
<li>Understanding the UK-US Valuation Gap.</li>
<li>Reviving the UK Market Through Listing and Pension Reforms.</li>
<li>US Listings: Not Always Greener for UK Companies.</li>
<li>Outlook for 2025 and Key Desires.</li>
</ul>text4 minenglobal1/templatedata/rbccm/authors/data/adam-milleradam-millerAdam MillerHead, Corporate BrokingN/assets/rbccm/images/authors/adam-miller.jpg<div class="TypographyPresentation TypographyPresentation--medium RichText3-paragraph--withVSpacingNormal RichText3-paragraph"><strong>Adam Miller</strong> is Head of Corporate Broking. Adam joined RBC Capital Markets in 2024, bringing extensive coverage expertise from a twenty-year career at Merrill Lynch, Collins Stewart, Deutsche Bank, and HSBC. He was most recently a Managing Director in HSBC's UK Investment Banking team for six years, with significant connectivity with UK boardrooms across various industries.</div>Hosted by <b>Adam Miller</b>Hosted by <b>Adam Miller</b>1insights, european insightsLast week's U.K. Focus Conference, hosted by Adam Miller of RBC Capital Markets, brought together top minds to discuss the U.K.'s investment landscape.There are six key takeaways.U.K. equities market, M&A, Regulatory reform, U.K. capital markets, Pensions, Pension reform, Active managementU.K. Equities, M&A, Regulatory reform, U.K. capital markets, Pensions, Pension reform, Active management
Why invest in the U.K.? Five takeaways from the 2025 U.K. Focus Conference
Last month, we held the inaugural U.K. Focus Conference, hosted by Adam Miller, Head of U.K. Corporate Broking at RBC Capital Markets, where we invited investors to hear from Charlie Walker, Deputy Chief Executive Officer at the London Stock Exchange Plc; Adam McConkey, Head of Team & Co-Lead Portfolio Manager at Lombard Odier; and Anne Christine Farstad, Equity Portfolio Manager at MFS Investment Management, sharing their insights in a session on the key drivers and opportunities in the U.K.
Hosted by Adam Miller Published | 4 min
read
Key points
The US Outperformed the European Markets Again in 2024.
Understanding the UK-US Valuation Gap.
Reviving the UK Market Through Listing and Pension Reforms.
US Listings: Not Always Greener for UK Companies.
Outlook for 2025 and Key Desires.
The U.K. equity market took center stage in a recent discussion featuring industry leaders exploring key developments from 2024 and trends shaping 2025. Charlie Walker, Deputy Chief Executive Officer at the London Stock Exchange Plc; Adam McConkey, Head of Team & Co-Lead Portfolio Manager at Lombard Odier; and Anne Christine Farstad, Equity Portfolio Manager at MFS Investment Management, shared their insights in a session moderated by Adam Miller, Head of U.K. Corporate Broking at RBC Capital Markets.
With questions around the U.K.’s positioning in global markets, the conversation delved into a critical theme: the gap between perception and reality in U.K. equities.
1. The US Outperformed the European Markets Again in 2024
The S&P 500 had an impressive year, rising by 23% though heavily influenced by gains by the 'Mag 7' tech giants. Excluding these seven companies, the S&P 500 gained a more modest 7%
In contrast, the UK market has lagged behind, partly due to underlying skepticism and a lack of investor confidence which does not reflect the actual market fundamentals
The discussion highlighted a critical underlying issue where UK equities have been overshadowed by their US counterparts, exacerbating the performance gap
2. Understanding the UK-US Valuation Gap
The valuation disparity between UK and US markets is significant, with an 8x PE valuation gap, and when including the 'Mag 7', this gap widens to 12x
Global momentum investing, where investment decisions are driven by recent performance rather than fundamental value, has favored US markets
This approach is tied to US exceptionalism and a higher RoE of around 20% compared to the UK's 15% and Japan's 10%
UK markets need to promote their value proposition strategically to bridge this gap and attract global investment
3. Reviving the UK Market Through Listing and Pension Reforms
Recent years in the UK have been dominated by major events such as Brexit and the COVID-19 pandemic
It's only in the last 18 months that policy changes and regulatory reforms, like new listing rules, have become the focus for the UK
Notably, the discussion about the pensions industry is pivotal, given that UK pension allocations to UK assets have plummeted from 48% in 2000 to between 5-10% now
The UK has the second-largest pool of long-term capital globally, and the country needs to harness this capital better to support its domestic market and attract new listings
4. US Listings: Not Always Greener for UK Companies
There's a prevalent perception that the US market is far superior, leading many UK companies to list in the US
However, the data shows a mixed results: 20 of the UK companies that listed in the US in the past 10 years have had varied success with eight trading down by 79% on average, four doing well (like ARM), and eight delisted for diverse reasons, suggesting that the grass is not always greener on the other side
The challenge for the UK is to support its companies better through the various growth stages domestically, preventing capital and talent from migrating to the US
5. Outlook for 2025 and Key Desires
Corporate confidence in the UK is relatively high, especially with current valuations
A key point of discussion was the prevalent public M&A activity in the UK, with companies being acquired at premiums of 75%-100%. This seems to contradict the negative sentiment around UK stocks, suggesting that despite low perceived growth and mature stories, there is significant value there
The panel speakers agreed on the need for ongoing pension reforms to foster a more robust equity culture, akin to the 401k system in the US, which could stabilize and grow the market
Additionally, the speakers expressed hope for a relative underperformance of momentum strategies, signaling a shift away from the current trend-centric investing towards more fundamentally driven decisions
Overall, the panelists agreed that the UK continues to be a compelling investment across a number of asset classes. If policy reforms through 2025 can continue to reinvigorate interest in the market and bring new companies to investors’ attention, the outlook will continue to be positive.
Related content
Our experts
Adam Miller
Head, Corporate Broking
More insights
Stay informed
Get the latest insights and news from RBC Capital Markets delivered to your inbox.